• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Proteinuria: clinical signficance and basis for therapy.

作者信息

Woo K T, Lau Y K

机构信息

Department of Renal Medicine, Singapore General Hosptial, Singapore.

出版信息

Singapore Med J. 2001 Aug;42(8):385-9.

PMID:11764058
Abstract

Proteinuria is the hallmark of renal disease and proteinuria exceeding 1 gm a day in patients with renal disease augers a poorer prognosis. Proteinuria has been shown to be tubulotoxic and directly contributes to renal deterioration. Patients with non-selective proteinuria are more likely to have progressive renal disease. Diabetic patients with persistent microhaematuria have about 20 times the risk of developing diabetic nephropathy. In essential hypertension, the onset of de novo proteinuria after years of adequate BP control is a marker of subsequent decline in renal function. In glomerulonephritis, more severe proteinuria is associated with faster rate of progression. Even though the initial phase of proteinuria in patients with glomerulonephritis is usually of immunological origin, in the vast majority of patients with established disease, the latter progressive phase of proteinuric glomerulopathy is the result of glomerular hyperfiltration which shifts glomerular non-selective pores to larger dimensions resulting in excessive leakage of protein in the urine. Endothelial injury resulting from glomerular hyperfiltration causes increase in local generation of Angiotensin II in the kidney as part of the hemodynamic response. ACE inhibitors and angiotensin II receptor antagonists (ATRA) can improve glomerular pore-selectivity by remodelling the glomerular basement membrane. In addition, these agents also have beneficial effects by decreasing TGF-beta production therapy decreasing mesangial cell proliferation, hence ameliorating disease progression in patients with diabetic nephropathy and IgA nephropathy. A number of recent clinical trials have shown that ACEI and ATRA therapy can retard the progression of renal deterioration in patients with NIDDM and those with IgA nephropathy and even restore normal renal function in those with mild renal impairment. Treatment and control of proteinuria in patients with renal disease should be regarded as important as treatment of hypertension as it can prevent renal failure.

摘要

相似文献

1
Proteinuria: clinical signficance and basis for therapy.
Singapore Med J. 2001 Aug;42(8):385-9.
2
The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.血管紧张素转换酶基因多态性对马来西亚患者免疫球蛋白A肾病进展的影响。
Singapore Med J. 2008 Nov;49(11):924-9.
3
Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?糖尿病和非糖尿病慢性肾脏病中通过阻断肾素-血管紧张素-醛固酮系统实现的肾脏保护作用。肾内血管紧张素转换酶活性在治疗抵抗中的具体作用?
Minerva Med. 2004 Oct;95(5):395-409.
4
Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats.血管紧张素转换酶抑制与血管紧张素II受体阻断对雄性MWF/Ztm大鼠自发性肾小球损伤进展影响的比较
Exp Nephrol. 1996 Jan-Feb;4(1):19-25.
5
Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.慢性肾脏病中血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的处方用药
Nephrology (Carlton). 2007 Feb;12(1):81-9. doi: 10.1111/j.1440-1797.2006.00749.x.
6
Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.在糖尿病肾病中,肾功能下降与蛋白尿及早晨收缩压相关。
Clin Exp Hypertens. 2005 Feb-Apr;27(2-3):129-38.
7
Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis.IgA 肾病中的疾病进展、对 ACEI/ATRA 治疗的反应及 ACE 基因的影响
Cell Mol Immunol. 2007 Jun;4(3):227-32.
8
Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.肾素-血管紧张素系统抑制剂可降低严重肾功能不全患者的肾小球滤过率下降速率及终末期肾病发生率。
J Nephrol. 2002 Jul-Aug;15(4):428-30.
9
Advances in the treatment of diabetic renal disease: focus on losartan.糖尿病肾病治疗进展:聚焦氯沙坦
Curr Med Res Opin. 2004 Mar;20(3):333-40. doi: 10.1185/030079903125003107.
10
ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.血管紧张素转换酶抑制剂/全反式维甲酸疗法通过改善IgA肾病的肾小球滤过选择性来降低蛋白尿。
Kidney Int. 2000 Dec;58(6):2485-91. doi: 10.1046/j.1523-1755.2000.00432.x.

引用本文的文献

1
Corticosteroids in IgA Nephropathy: Lessons from Recent Studies.IgA肾病中的皮质类固醇:近期研究的经验教训
J Am Soc Nephrol. 2017 Jan;28(1):25-33. doi: 10.1681/ASN.2016060647. Epub 2016 Sep 26.
2
Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.研究肾病对单克隆抗体处置的影响:糖尿病肾病小鼠模型中的药代动力学研究。
Pharm Res. 2014 May;31(5):1185-93. doi: 10.1007/s11095-013-1241-y. Epub 2013 Nov 8.